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Abstract
Recent evidence suggests that increased psychophysiological response to negatively valenced emotional
stimuli found in major depressive disorder (MDD) may be associated with reduced catecholaminergic neuro-
transmission. Fourteen unmedicated, remitted subjects with MDD (RMDD) and 13 healthy control subjects
underwent catecholamine depletion with oral α-methyl-para-tyrosine (AMPT) in a randomized, placebo-
controlled, double-blind crossover trial. Subjects were exposed to fearful (FF) and neutral faces (NF) during
a scan with [15O]H2O positron emission tomography to assess the brain–catecholamine interaction in brain
regions previously associated with emotional face processing. Treatment with AMPT resulted in signiﬁcantly
increased, normalized cerebral blood ﬂow (CBF) in the left inferior temporal gyrus (ITG) and signiﬁcantly
decreased CBF in the right cerebellum across conditions and groups. In RMDD, ﬂow in the left posterior cingu-
late cortex (PCC) increased signiﬁcantly in the FF compared to the NF condition after AMPT, but remained un-
changed after placebo, whereas healthy controls showed a signiﬁcant increase under placebo and a signiﬁcant
decrease under AMPT in this brain region. In the left dorsolateral prefrontal cortex (DLPFC), ﬂow decreased
signiﬁcantly in the FF compared to the NF condition under AMPT, and increased signiﬁcantly under placebo
in RMDD, whereas healthy controls showed no signiﬁcant differences. Differences between AMPT and placebo
of within-session changes in worry-symptoms were positively correlated with the corresponding changes in
CBF in the right subgenual prefrontal cortex in RMDD. In conclusion, this study provided evidence for
a catecholamine-related modulation of the neural responses to FF expressions in the left PCC and the left
DLPFC in subjects with RMDD that might constitute a persistent, trait-like abnormality in MDD.
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Introduction
Altered processing of negatively valenced emotional
stimuli has been consistently found in MDD. However,
the neurobiological underpinnings and the pathogenetic
relevance of abnormal reactions to such stimuli in MDD
have not yet been fully elucidated. One established
method to examine the processing of negative stimuli
involves the exposure to pictures of human faces portray-
ing fearful expressions. Previous research found that the
response to fearful faces (FFs) in MDD is associated
with increased activity in brain regions associated with
emotional evaluation (i.e. amygdala, orbitofrontal cortex
(OFC), striatum) (Cavassila et al., 1999; Drevets, 2000;
Fales et al., 2008) and decreased activity in regions associ-
ated with emotional regulation (i.e. dorsolateral pre-
frontal cortex (DLPFC), anterior cingulate cortex (ACC))
(Johnstone et al., 2007; Siegle et al., 2007; Fales et al.,
2008). These ﬁndings appear partly compatible with a
model of emotional processing that involves top-down
regulation of limbic and subcortical structures associated
with rapid processing of emotionally salient stimuli
(Mayberg, 1997; Phillips et al., 2008) by the DLPFC and
OFC (Ochsner et al., 2002; Phillips et al., 2008).
Interestingly, it has been found that a single dose of
reboxetine, a norepinephrine reuptake inhibitor, reversed
the altered response to happy faces in depressed subjects,
suggesting that catecholamines are involved in the modu-
lation of emotional processing at a very early stage in
antidepressant treatment, before symptom changes
are evident (Harmer et al., 2009). These data, taken
together with evidence that catecholamines affect func-
tions of the limbic–cortical–striatal–pallidal–thalamic
circuitry implicated in the pathophysiology of MDD
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(Hasler et al., 2008; Price and Drevets, 2010), suggest
that examination of brain–catecholamine interactions
in cerebral structures associated with the differential
neural response to FF stimuli in MDD subjects vs. healthy
controls may illuminate the neural bases of the negative
emotional processing biases associated with MDD (Victor
et al., 2010; Harmer et al., 2011). The current study aimed
to address this goal without the potential confound of
a medication bias (Stuhrmann et al., 2011) by assessing
unmedicated, fully remitted patients with MDD (RMDD)
during exposure to neutral and fearful facial expressions.
To study the brain–catecholamine interaction, subjects
received either placebo or alpha-methyl-para-tyrosine
(AMPT) (Berman et al., 1999) before the [15O]H2O-positron
emission tomography (PET) scan. AMPT competitively
inhibits tyrosine hydroxylase, the rate-limiting enzyme in
catecholamine synthesis, and is, therefore, able to decrease
catecholaminergic neurotransmission by depleting central
dopamine and norepinephrine stores (Stine et al., 1997;
Verhoeff et al., 2003). Given that previous research found
an increased activity in subcortical brain regions and a
decreased top-down control by the DLPFC in response
to FFs, we hypothesized that catecholamine depletion
with AMPT but not placebo would result in an increased
behavioral response to FFs in RMDD but not in healthy
controls, and in an increased hemodynamic response in
the limbic–striatal–pallidal–thalamic circuit along with a
decreased response in the DLPFC.
Methods
The current study was part of a larger project that inves-
tigated the role of catecholamines in the pathogenesis of
MDD. To this end, we assessed the behavioral, neuro-
psychological and neurobiological response to catechola-
mine depletion in subjects with low and high risk of
depression. The neuropsychological assessment included
the behavioral and hemodynamic responses to FFs. FFs
were used to activate the stress system that is thought
to be overactive in depression. Speciﬁcally, using a
double-blind, placebo-controlled, crossover design, fully
remitted, unmedicated participants with MDD were
studied under catecholamine depletion as well as under
placebo administration. During the depletion procedures,
cerebral blood ﬂow (CBF) was assessed using [15O]H2O
PET to measure the neural response to emotionally
valenced stimuli. Afterwards, the study participants
also underwent [18F]-ﬂuordeoxyglucose PET scanning to
compare metabolic correlates of catecholamine depletion
between RMDD subjects and healthy controls, and neuro-
psychological testing, from which the results have been
reported previously (Hasler et al., 2008, 2009).
Participants
The experimental group comprised individuals aged
18–56 yr who met DSM-IV criteria for MDD in full
remission. The healthy controls had no personal history
of any psychiatric disorder and no family history of a
major psychiatric disorder in ﬁrst-degree relatives.
Diagnosis was established using the Structured Clinical
Interview for DSM-IV (First, 2001) and conﬁrmed by an
unstructured interview with a psychiatrist. The subjects
were recruited through the outpatient clinical services of
the National Institute of Mental Health and by advertise-
ments in local newspapers and posters on the National
Institutes of Health (NIH) campus. Exclusion criteria in-
cluded major medical illnesses, pregnancy, psychotropic
drug exposure (including nicotine) within 3months, sub-
stance abuse within 1 yr, lifetime history of substance
dependence, psychiatric disorders other than MDD, and
structural brain abnormalities on MRI. Inclusion criteria
required that RMDD subjects had remained in remission
without medications for at least 3 months and had mani-
fested depression onset before 40 yr of age. Written
informed consent was obtained as approved by the
Combined Neuroscience Institutional Review Board of
the NIH.
Experimental design
Using a randomized, double-blind, placebo-controlled
crossover design, subjects underwent two identical ses-
sions separated by at least 1 wk, in which they received
either a body-weight adjusted AMPT dose or placebo
(see (Hasler et al., 2008) for details). To reduce risk of
adverse reactions, a body-weight adjusted AMPT dose
of 40mg/kg of body weight orally, to a maximum of
4 g, over 22 h was used. Each session took 3 d and was
performed on an inpatient basis at the NIH Clinical
Center. To reduce the risk of crystalluria during AMPT
administration, subjects received sodium bicarbonate,
drank at least 2 l of water daily, and underwent urinalysis
twice daily. During the PET scan, blocks of FF stimuli
were alternated with control scans in which the faces
showed a neutral expression (NF). Behavioral ratings in-
cluded a visual analog scale (VAS) of three different
emotional dimensions (anxiety, sadness, worry). Ratings
were conducted inside the camera by short interviews
with the research subjects after a series of faces with the
same emotional expression were presented, i.e. at the be-
ginning of the interval between blood ﬂow scans. In ad-
dition, as a pharmacodynamic assessment to verify
target engagement within the central nervous system,
the effect of AMPT on serum prolactin levels was
measured.
Statistical analysis of behavioral data
To account for the repeated measurements in the same
subjects, full factorial linear mixed models with restricted
maximum likelihood estimations were used to examine
the effects of the primary and secondary outcome mea-
sures. Schwarz’s Bayesian criteria were used to determine
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the best ﬁtting covariance structure for each set of mea-
sures in cases where the typical compound symmetry ap-
proach used by ANOVA did not provide the optimal
structure for the extant data. The effects of treatment,
diagnosis, and stimulus on the VAS scores were assessed
with linear mixed models with a ﬁrst-order autoregres-
sive covariance structure. The effects of treatment, diag-
nosis, and time on prolactin levels were assessed with
linear mixed models with a ﬁrst-order autoregressive
covariance structure. Subject number and treatment
sequence were included as random effects in all models.
Post-hoc t-tests involved a Tukey-correction for multiple
comparisons. The signiﬁcance thresholds for these con-
trasts were set at α=0.05, two-tailed. SAS 9.3 (SAS
Institute Inc., USA) was used for all analyses. The
means of the data are reported with their associated
standard deviation (S.D.).
[15O]H2O-PET imaging
The PET scanning was performed during the expected
nadir of plasma catecholamine levels on the second day
of AMPT administration. Subject preparation consisted
of intravenous catheterization and immobilization of the
head using a thermoplastic mask. PET scans were
acquired using a GE Advance (35 contiguous slices
with 4.25mm plane separation; 3D resolution=6–7mm
FWHM, 3D acquisition mode). (Townsend et al., 1998)
First, a transmission scan (about 8min) using rotating
rods of 68Ge/68Ga with electronic windowing around
the rods to minimize scatter was obtained for attenuation
correction of the emission scans during the tracer uptake
period. (Huang et al., 1979) Following transmission
scan, ﬁve CBF scans were acquired at an 8min inter-scan
interval using bolus injection of 10mCi of [15O]H2O.
To provide an anatomical framework for analysis of
the PET images, structural MRI scans were acquired
with a 3.0-T scanner (Signa; GE Medical Systems) and
a T1-weighted pulse sequence (magnetization prepared
rapidly acquired gradient echo (MP-RAGE); voxel size,
0.9×0.9×1.2 mm).
Behavioral task
Gray-scale, static face picture stimuli (Ekman, 1976) mod-
iﬁed as previously described by Morris et al. (1996) were
presented during each scan. These stimuli depicted the
faces of actors and actresses displaying multiple distinct
emotional expressions. The photographs were digitized
and modiﬁed by cropping out hair, neck, and ears,
achieving isoluminance across stimuli, and centering
each face’s eyes so they appeared in a uniform location
on the computer monitor, as described and illustrated
in Morris et al. (1996, 1998). The photographed subject’s
eyes provide a natural ﬁxation point for the viewers’
gaze. Since we were only interested in determining the
responses to a block of emotionally expressive faces that
are of a single emotion, within an individual scan all
face stimuli shown were of the same emotional valence,
and face pictures depicting different grades of a particular
emotion (e.g. moderately vs. markedly fearful) were dis-
played in random order within a particular scan. Scans
containing blocks of FF stimuli were alternated with
control scans containing blocks of NF stimuli. The FFs
were presented in two different blood ﬂow scans. To
reduce order effects, the sequence in which either NF or
FF types were presented was counterbalanced across
subjects. The task instructions were the same for all
scans, as subjects were asked to indicate the gender of
each face by pressing the left button on a two-button
ﬁberoptic key pad for male and the right for female
(Morris et al., 1996). Stimulus presentation was initiated
approximately 7 s before the start of the emission scan
to minimize the amount of habituation that may occur
prior to the arrival of the 15O bolus to the head (the
ﬁxation point CBF scan that precedes the experimental
scans permitted estimation of the lag time between
[15O]H2O injection and the rise in radioactive counts
from the head). The face stimuli were displayed at one
Hz on a Macintosh computer monitor using Super
Lab™ software. This frequency was selected because in
pilot studies it permitted adequate time to assign gender,
and the short stimulus duration minimized the likelihood
of scanning eye movements. Eye movement was not evi-
dent during random checks during stimulus presentation,
as at the 1Hz rate of stimulus presentation, the exper-
imental subject’s eyes usually remain ﬁxed on the pic-
tured subject’s eyes and do not scan the faces. Starting
with a ﬁxation point control (Fx Pt), the subjects were ran-
domized to one of two possible scan sequences within
each group: 1. Fx Pt–FF–NF–FF–NF, 2. Fx Pt–NF–FF–
NF–FF.
Analysis of PET image data
Matlab (Matlab v.7, release 2010b; The MathWorks,
Inc., USA), SPM8 (Wellcome Trust Centre for Imaging,
England; www.ﬁl.ion.ucl.ac.uk/spm8), and the toolbox
aslm (Homan et al., 2012) were used for image analysis.
The PET images were co-registered to each subject’s
structural image, spatially normalized to the Montreal
Neurological Institute brain template and smoothed
using a 6mm gaussian smoothing kernel. The statistical
models that were applied to compare the CBF across stim-
uli, treatments and diagnostic groups included the main
effects of FF vs. NF stimuli, placebo vs. drug, patients
vs. healthy controls, and subject. In a ﬁrst step, the ﬂexible
factorial model in SPM8 was used to model each subject’s
response to FF and NF stimuli for AMPT and placebo,
respectively. The contrast images then were used in a se-
cond level analysis, in which the three-way interaction
(stimulus× treatment×diagnosis) was assessed in a two-
sample t-test of both diagnostic groups (i.e. RMDD and
Catecholamine depletion and fearful faces 3
healthy controls). A priori hypotheses were tested by
assessing changes in the predeﬁned ROI including
the amygdala, DLPFC, medial and lateral OFC, hippo-
campus, anteroventral striatum (AVS), thalamus, pos-
terior cingulate cortex (PCC) and the subgenual and
pregenual ACC. These ROI were selected according to
the ﬁndings and model of Drevets and Price (Drevets
et al., 1992; Price and Drevets, 2010) using anatomic
boundaries and methods as described by Drevets et al.
(2001) and Neumeister et al. (2004). To assess changes
in the normalized blood ﬂow the regional tissue radio-
activity was scaled to the global activity, and then com-
pared across conditions using the Small Volume
Analysis option within SPM8 software to evaluate the
signiﬁcance of group differences in the contrasts obtained
in the second level analysis.
In order to assess AMPT-induced CBF changes across
the whole brain, an exploratory voxelwise analysis of
the PET data also was performed post-hoc. Additional
correlational analyses were performed using the beha-
vioral VAS scores for anxiety, sadness, and worry as
covariates of interest in the second level analysis.
Therefore, the difference between the within-session
behavioral score change between the FF and the NF
condition for each subject in the AMPT session vs. the
placebo session was calculated to reﬂect the magnitude
of the AMPT-induced effect on symptom ratings. In
ROI for which we had a priori hypotheses, results were
small-volume corrected for familywise error, and reported
at a voxel-level threshold of p<0.05. Additional clusters
derived from the whole-brain analysis are reported with
a voxel-level threshold of p<0.05, whole-brain corrected
for familywise error. For signiﬁcant regions, β estimates
of regional CBF were extracted in order to calculate
post-hoc tests and to depict the direction of the three-
way-interaction.
Results
The clinical and demographic characteristics of the subject
samples are detailed in Table 1.
From 28 subjects, 14 subjects with RMDD and
13 healthy controls were included in the study. One
female subject with RMDD did not participate in
the [15O]H2O-PET imaging. The 13 healthy volunteers
(12 females; mean±[S.D.] age=39±10 yr) were not signiﬁ-
cantly different from the 14 RMDD subjects (13 females;
mean±S.D. age=38.1±11 yr) with respect to gender ratio
and mean age.
Behavioral results
Behavioral results of catecholamine depletion compared
to placebo in RMDD subjects and healthy controls as
measured with the Montgomery–Åsberg Depression
Rating Scale (MADRS), Hamilton Rating Scale for
Depression (HAMD), and Beck Anxiety Inventory (BAI)
have been published previously (Hasler et al., 2008).
Brieﬂy, depressive symptoms were increased after the
administration of AMPT to a greater extent in subjects
with RMDD than in healthy controls, and anxiety ratings
also increased in RMDD under catecholamine depletion,
whereas the corresponding changes in healthy subjects
were statistically not signiﬁcant.
Figure 1 shows VAS scores of anxiety, sadness, and
worry categorized by stimulus, treatment, and diagnosis.
Anxiety scores as measured after each condition using
the VAS were higher in the FF compared to the NF con-
ditions in the whole group (F1,203=6.09, p=0.01), and
were signiﬁcantly higher in the RMDD subjects compared
to the controls (F1, 203=12.58, p=0.0005) as well as under
AMPT administration compared to placebo (F1,203=
12.84, p=0.0004). The stimulus×diagnosis interaction
also was signiﬁcant (F1,203=7.81, p=0.006); this interaction
Table 1. Demographic and clinical characteristics of unmedicated subjects with remitted
major depressive disorder (RMDD) and healthy controls
Characteristic RMDD (n=14) Controls (n=13)
Sex, No. females/males 13/1 12/1
Age, mean (S.D.), yr 38.1 (11) 39 (10)
Age at onset, mean (S.D.), yr 23 (8.2) NA
Past Major Depressive Episodes, mean (S.D.), No. 2.5 (1.3) 0
Time in remission, months
Mean (S.D.) 33 (29) NA
Range 7–118 NA
First-degree relative(s) with a mood disorder, No. 14 0
Remote (>1 yr ago) history of alcohol abuse, No. 3 1
History of drug abuse, No. 0 0
MADRS score at study entry, mean (S.D.) 1.4 (2.2) 0.4 (0.9)
Abbreviations: f/m, female/male; MADRS, Montgomery–Åsberg Depression Rating Scale;
NA, not applicable; S.D., standard deviation.
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was attributable to higher anxiety scores in the FF
condition in RMDD subjects compared to controls
(t1, 203=4.19, p=0.0002) and in the FF compared to the
NF conditions in RMDD (t1,95=3.76, p=0.001). The ratings
of sadness were higher in the FF compared to the NF
conditions in the whole group (F1,203=8.6, p=0.004), and
there was a stimulus-by-diagnosis interaction evident
(F1,203=12.98, p=0.0004) that was attributable to higher
sadness in the FF compared to the NF condition in
RMDD (t1,203=4.67, p<0.0001). The VAS scores of worry
were higher in RMDD subjects compared to controls
(F1,203=4.83, p=0.03).
The central effect of AMPT was evidenced by an
increase of serum prolactin levels following catechola-
mine depletion (F1, 25=361.87, p<0.0001), and no effect
of diagnosis (p=0.69) or treatment×diagnosis interaction
(p=0.97) were evident.
[15O]H2O-PET imaging results: ROI analysis
Figure 2 shows the ROI analysis of the PCC, where a sign-
iﬁcant stimulus× treatment×diagnosis interaction was
evident in the PCC cortex corresponding to Brodmann
area 30, situated on the posterior cingulate gyrus and
the anterior-most aspect of the cuneate gyrus (peak: x, y,
z=−8, −60, 8; cluster-size: 38 voxels; t25=5.65, p<0.05,
small-volume corrected for familywise error). This inter-
action was attributable to an increased regional CBF in
the PCC as response to FFs under AMPT compared to
placebo for RMDD and a respective decrease in healthy
controls. The ROI analysis of the DLPFC revealed a signiﬁ-
cant stimulus× treatment×diagnosis interaction in the left
dorsolateral prefrontal cortex (Brodmann area 46; locus
for peak voxel t-value: x, y, z=−54, 26, 28; cluster-size:
25 voxels; t25=6.37, p<0.05, small-volume corrected for
familywise error; Figure 3). This interaction was attri-
butable to a decreased regional ﬂow with the FFs
under AMPT compared to an increased regional ﬂow
with the FFs under placebo for RMDD that was not
evident in healthy controls. No interaction was found
in the other ROI (amygdala, medial and lateral OFC,
hippocampus, AVS, thalamus, and ACC).
[15O]H2O PET imaging results: voxelwise analysis
After AMPT administration, blood ﬂow was higher in
the left inferior temporal gyrus (ITG), Brodmann area
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Fig. 2. (a) Stimulus× treatment×diagnosis interaction in the
region of interest selected according to the a prioiri hypotheses.
A cluster of 38 voxels was found in the posterior
cingulate cortex (PCC), corresponding to Brodmann area
30 (peak: x, y, z=−8, −60, 8; t25=5.65, p<0.05, small-volume
corrected for familywise error). (b) Mean beta estimates with
S.E. at the region of interest depicted in (a) categorized by
stimulus, treatment and diagnosis. *Indicates a signiﬁcant
difference in the post-hoc tests at p<0.05.
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20 (peak: x, y, z=−54, −11, −28; t26=7.47; p=0.004, cor-
rected for familywise error) and lower in the anterior
lobe of the right cerebellum (peak: x, y, z=28, −42, −38;
t26=7.77, p=0.002, corrected for familywise error) com-
pared to placebo across conditions and groups. Testing
for a stimulus-effect, a treatment-by-diagnosis interaction,
a stimulus×diagnosis interaction, a stimulus× treatment
interaction, and a stimulus× treatment×diagnosis inter-
action did not reveal any signiﬁcant results.
[15O]H2O PET imaging results: correlational analysis
Additional correlational voxelwise analyses were per-
formed including the difference (AMPT vs. placebo) of
within-session (FF vs. NF) changes of anxiety, sadness
and worry VAS scores as covariates. There was a positive
association of the AMPT-induced, within-session change
of worry VAS score and the corresponding CBF change
in the right subgenual prefrontal cortex (corresponding
to Brodmann area 10/32 (Ongur et al., 2003; Price and
Drevets, 2010); peak voxel t-value at: x, y, z=6, 34, −14;
t24=6.68; p<0.05, corrected for familywise error; Fig. 4).
Re-computing the correlational analysis for each group
separately revealed that RMDD showed a signiﬁcant
positive correlation of the AMPT-induced, within-session
change of worry VAS score and the corresponding
CBF change (r=0.89, p<0.0001) that was only present at
a trend-level in controls (r=0.48, p=0.09).
Discussion
To our knowledge, this is the ﬁrst study to compare the
effect of catecholamine depletion on the neural response
to FFs vs. NFs in unmedicated RMDD and healthy
controls. Catecholamine depletion was associated with
behavioral and neurophysiological effects that in some
cases were similar and in others were distinct in the
RMDD sample relative to the control sample. The
administration of AMPT increased anxiety in the entire
sample, and to a greater extent in RMDD. AMPT-
administration compared to placebo resulted in a higher
CBF in the left inferior temporal gyrus and a lower CBF
in the anterior lobe of the right cerebellum across con-
ditions and groups. In the left PCC ﬂow increased in
the FF compared to the NF condition after AMPT but
remained unchanged after placebo in RMDD, whereas
healthy controls showed an increase under placebo and
a decrease under AMPT. In the left DLPFC, ﬂow de-
creased in the FF compared to the NF condition under
AMPT and increased under placebo in RMDD, whereas
healthy controls showed no such differences. Differences
between AMPT and placebo of within-session changes
in worry symptoms were positively correlated with the
corresponding changes in CBF in the right subgenual
prefrontal cortex in RMDD.
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corrected for familywise error).
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Fig. 3. (a) Stimulus× treatment×diagnosis Interaction in the
left dorsolateral prefrontal cortex, a region of interest selected
according to the a priori hypotheses. A cluster of 25 voxels
was found in Brodmann area 46 (peak: x, y, z=−54, 26, 28;
t25=6.37, p<0.05, small-volume corrected for familywise error).
(b) Mean beta estimates with S.E. at the region of interest
depicted in (a) categorized by stimuli, treatment and diagnosis.
*Indicates a signiﬁcant difference in the post-hoc tests at p<0.05.
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The current study applied catecholamine depletion
with AMPT to assess the brain–catecholamine interaction
of cortical structures responding to fearful emotional
stimuli. Consistent with our a priori hypothesis, the beha-
vioral responses were higher levels of anxiety in RMDD
compared to controls in response to FFs, supporting
previous ﬁndings that found that the risk for MDD is
associated with an increased sensitivity to fearful stimuli
(Bhagwagar et al., 2004; Neumeister et al., 2006; Norbury
et al., 2010). However, since both RMDD subjects and
controls showed more anxiety under AMPT compared
to placebo, the change in anxiety under catecholamine
depletion did not have a differential effect on RMDD in
this study sample.
The behavioral response to FFs was associated with
regional hemodymanic responses. In two regions of the
limbic–cortical–striatal–pallidal–thalamic circuitry where
we had a priori hypotheses, AMPT-induced changes in
blood ﬂow between the FF and NF conditions differed
signiﬁcantly between groups. With respect to the PCC,
monosynaptic anatomical connections have been de-
scribed previously between this region and the rostral
ACC (Saleem et al., 2008; Price and Drevets, 2010),
which extends into the subgenual prefrontal cortex region
implicated herein, and forms part of the medial prefrontal
(visceromotor) network (Price and Drevets, 2010) impli-
cated in the pathophysiology of depression (Drevets
et al., 2002; Neumeister et al., 2004; Hasler et al., 2008),
as well as in the processing of self-consciousness (Kjaer
et al., 2002; Lou et al., 2004) involved in the ‘default
mode network’ that has been shown to be aberrant in de-
pression (Sheline et al., 2009). Furthermore, studies exam-
ining neural face processing found less functional
connectivity of the precuneus and the OFC in patients
with MDD (Frodl et al., 2010) and aberrant neural
responses in this extrastriatal area (Lawrence et al.,
2004; Fu et al., 2007) that might be mediated by intercon-
nections with the amygdala (Haxby et al., 2002; Phillips
et al., 2003). Inconsistent with our a priori hypothesis,
no difference in the amygdala response to FFs was
found in the current study. Notably, the functional con-
nectivity of the amygdala response to negatively valenced
faces, which previously was reported to be abnormal in
depression by Fu et al. (2007), could not be assessed
using PET data due to the limited numbers of images
obtained per condition. Fu et al., also found that the
PCC showed decreased activation in response to happy
faces in patients with MDD which improved signiﬁcantly
upon treatment with antidepressants. However, in con-
trast to our study, the authors assessed the response to
happy faces, and the patients were treated with ﬂuoxe-
tine, a selective serotonin reuptake inhibitor, which limits
the comparability to our study. The study populations in
the studies by Lawrence et al., and Frodl et al., comprised
subjects with MDD who were receiving medications at
the time of scanning (Lawrence et al., 2004; Frodl et al.,
2010), which also limits the comparability to our study.
Due to our different study design involving subjects
with RMDD, our study adds to the aforementioned
ﬁndings by showing that the distinct CBF-response com-
pared to healthy controls may reﬂect a risk factor
for MDD that is associated with catecholaminergic
neurotransmission.
The reduction in CBF in the left DLPFC in the FF com-
pared to the NF condition under AMPT in RMDD impli-
cates a region within the prefrontal cortex that has been
associated with voluntary and automatic emotional pro-
cessing (reviewed in Price and Drevets (2010)). Previous
PET studies found decreased resting-activity in the
left DLPFC in individuals with MDD (Baxter et al.,
1989; Bench et al., 1993), and more recent functional mag-
netic resonance imaging (fMRI) studies of emotional face
processing in MDD have shown reduced DLPFC activity
in response to negative facial expressions (Fu et al., 2004;
Surguladze et al., 2005; Siegle et al., 2007). Notably, most
of these ﬁndings have been localized to the left hemi-
sphere, in line with a proposed hemispheric localization
of emotion (Davidson, 1992) and lesion-based studies in
MDD (Shimoda and Robinson, 1999). In addition, pre-
vious neuroimaging studies in RMDD have conﬁrmed
abnormalities in the left DLPFC and, therefore, suggest
that alterations in this region might be a trait marker
in MDD (Liotti et al., 2002; Neumeister et al., 2006;
Norbury et al., 2010; Victor et al., 2010; Kerestes et al.,
2012), although those studies included medicated subjects
(Liotti et al., 2002) or subjects with co-morbid illnesses
(Neumeister et al., 2006; Norbury et al., 2010), which lim-
its conclusions that can be drawn about trait markers of
MDD. A recent study in unmedicated MDD subjects
reported reduced hemodynamic activity in response to
FFs in the left DLPFC (Kerestes et al., 2012), which is sup-
ported by our ﬁnding and extended by the observation
that the increase in regional CBF in the left DLPFC in re-
sponse to FFs under placebo that was inverted by AMPT
might reﬂect a top-down control of anxiogenic stimuli
depending on catecholaminergic neurotransmission.
The fact that healthy controls showed a decreased ﬂow
under catecholamine depletion when presented FFs com-
pared to NFs, whereas subjects with RMDD showed an
increased ﬂow when presented FFs compared to NFs,
might indicate that brain activity in the PCC can be inter-
preted as compensatory brain activity that would usually
maintain remission in RMDD but is vulnerable to a de-
pletion of catecholamines. Compensatory brain activity
has been suggested as a counter-measure used by the
brain to cope with depression (Lewis, 2000; Norbury
et al., 2010; Kessler et al., 2011), i.e. ‘an augmentation of
existing circuits to (unsuccessfully) cope with the disease’
(Kessler et al., 2011). The fact that AMPT led to a ‘normal-
ization’ of ﬂow in the DLPFC suggests that this brain re-
gion shows catecholamine-dependent activity associated
with remission in RMDD.
Finally, there was an association of the behavioral and
the neural response to FFs that was evidenced by the
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positive correlation of within-session changes in worry-
symptoms and the corresponding CBF changes in a
small locus within the right medial frontal gyrus (MFG).
The greater the difference in CBF in the right MFG be-
tween the FF and the NF tasks and between the AMPT
and placebo conditions, the more worry-symptoms
were expressed by the RMDD subjects. The right MFG
may be viewed as an interface mediating prefrontal
and limbic neurotransmission within the limbic–cortical–
striatal–pallidal–thalamic circuit implicated in the patho-
physiology of MDD (Hasler et al., 2008; Price and
Drevets, 2010). Speciﬁcally, our ﬁnding suggests that
the risk for MDD reﬂected by an increase in worry-
symptoms is associated with an interaction of limbic
and cortical regions mediated by increased activity in
the right MFG.
The current study had several limitations. The study
sample was relatively small and predominantly consisted
of female subjects. Since we did not include an additional
condition with emotional stimuli except FFs, we cannot
rule out that the observed emotion effects represent gen-
eral effects for any emotional stimuli. Next, our method
of PET imaging did not allow us to assess central catecho-
lamine concentrations, and we did not measure plasma or
urinary catecholamine levels to monitor the magnitude
of catecholamine depletion achieved. Since there is no
consistent association of central and peripheral catechola-
mine levels, we assessed the central AMPT-effect in-
directly by measuring serum prolactin levels, which is
the standard method to assess the effect of central
catecholamine depletion (Hasler et al., 2008, 2009). An
additional limitation is the relatively large range of
remission-time in the RMDD sample, a possible confoun-
der that may have had an impact on catecholaminergic
neurotransmission in the brain regions found in the cur-
rent study, for instance for reasons of age-related declines
in CBF. However, we tried to take this possible confoun-
der into account by repeating the SPM analysis including
remission-time in a correlational analysis in RMDD only
without any signiﬁcant results, using a signiﬁcance thresh-
old of p<0.05 and a familywise error correction for mul-
tiple comparisons. We also repeated the SMP analysis
with age as a covariate of no interest in the whole sample,
which did not alter any of the results. In addition, no cor-
relations were found between age and CBF in a voxelwise
analysis using a signiﬁcance threshold of p<0.05 and a
familywise error correction for multiple comparisons. To
address the question of how the AMPT-induced depress-
ive symptoms might have inﬂuenced the hemodynamic
response to the face-paradigm, we calculated additional
voxelwise correlational analyses in SPM using the
MADRS, HAMD, and BAI scores as covariates, and did
not ﬁnd any signiﬁcant results at a signiﬁcance threshold
of p<0.05 and a familywise error correction for multiple
comparisons. This suggests that the hemodynamic
response to the face-paradigm was not associated with
the AMPT-induced depressive symptoms. Finally, the
AMPT-effect on the regional CBF response to emotional
stimulus processing was relatively subtle, and no associ-
ation with mood symptoms was evident in the corre-
sponding brain regions. It is noteworthy, however, that
the reversal of altered neural responses to affective face ex-
pression in unmedicated individuals with MDD occurs
early in the course of antidepressant treatment, before
symptom changes are evident (Harmer et al., 2009), sug-
gesting that clinically relevant neural responses precede
overt changes in symptoms.
The current study had several strengths that merit
comment. First, the [15O]H2O PET method enabled us
to study the AMPT-effect on normalized (i.e. regional/
global) CBF, which is coupled to normalized glucose
metabolism. We showed that the administration of
AMPT resulted in a CBF increase in the left ITG and a de-
crease in the anterior lobe of the right cerebellum. Second,
the use of NF as the control-condition allowed us to spe-
ciﬁcally assess the processing of facially expressed fear by
controlling for nonspeciﬁc aspects of processing face stim-
uli. Third, the fact that we induced a transient depressive
relapse with AMPT in RMDD allowed us to interpret our
ﬁndings as risk-factors for a depressive relapse.
Finally the participants were selected in the un-
medicated, remitted phase of MDD, so that nonspeciﬁc
effects of antidepressant drugs or of depressive episodes
(e.g. related to chronic stress or sleep deprivation) were
excluded.
In conclusion, the current study provided evidence
for a catecholamine-related modulation of the neural
responses in the left PCC and the left DLPFC to FF
expressions in subjects with RMDD that might
constitute a persistent, trait-like abnormality in MDD.
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